GlassScriptPhysician profile
Corey Ann Hay Conn
NPI 1891765285
$18,140.90
in general payments reported to CMS, 2019-2025
66 companies · $3,145 in 2025
The $3,145 reported for 2025 was more than what 86% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $1,484 · 2021: $2,569 · 2022: $5,324 · 2023: $2,156 · 2024: $2,005 · 2025: $3,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,981 · Travel and Lodging: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,981.12 |
| Travel and Lodging | $1,324.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,574.46 | 2019-2025 | Wavewriter Alpha Prime 16, Clinical Trial Product, Bionic Navigator |
| Nevro Corp. | $2,756.41 | 2019-2024 | Senza |
| Nutech Spine, INC. | $2,000.00 | 2022 | |
| Spinal Simplicity, LLC | $1,354.68 | 2022-2024 | Ha Minuteman G3-R |
| Abbvie INC. | $867.42 | 2020-2025 | Ubrelvy, Qulipta, Botox |
| Nalu Medical, INC. | $521.25 | 2021-2024 | Nalu Neurostimulation System |
| Allergan, INC. | $432.25 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $425.97 | 2019-2023 | Austedo Xr, Austedo |
| Lundbeck LLC | $411.93 | 2020-2024 | Vyepti |
| Pfizer INC. | $393.89 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $367.89 | 2022-2025 | Belbuca, Xtampza |
| Globus Medical, INC. | $355.83 | 2025 | Senza, Vyrsa V1 |
| Amgen INC. | $339.68 | 2021-2024 | Aimovig, Uplizna |
| Lilly USA, LLC | $283.56 | 2019-2023 | Emgality, Reyvow |
| Ucb, INC. | $258.17 | 2019-2025 | Briviact, Zilbrysq, Fintepla |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Ann Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.